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Summary 
Expression of  the bcl-2 gene has been shown to effectively confer resistance to programmed cell 
death under a variety of circumstances. However, despite a wealth of literature describing this 
phenomenon, very little is known about the mechanism of resistance. In the experiments de- 
scribed here, we show that bd-2 gene expression can result in an inhibition of cell division cy- 
cle progression. These findings are based upon the analysis of cell cycle distribution, cell cycle 
kinetics,  and relative phosphorylation of the  retinoblastoma tumor suppressor protein, using 
primary tissues in vivo, ex vivo, and in vitro, as well as continuous cell lines.  The effects of bd-2 
expression on cell cycle progression appear to be focused at the G1 to S phase transition, which is 
a critical control point in the decision between continued cell cycle progression or the induction 
programmed cell death. In all systems  tested, bcl-2 expression resulted in a substantial 30-60% 
increase in the length of G 1 phase; such an increase is very substantial in the context of other 
regulators of cell cycle progression, Based upon our findings, and the related findings of others, 
we propose a mechanism by which bd-2 expression might exert its well known inhibition of 
programmed cell death by regulating the kinetics of cell cycle progression at a critical control 
point. 
T 
he bcl-2  gene was  discovered by virtue of its location 
at the breakpoint of the t(14; 18) chromosomal translo- 
cation  found  in  most  human  follicular  lymphomas  (1). 
Since that time, bcl-2  expression has been shown to confer 
a resistance to programmed cell death (PCD) 1 in a variety 
of systems,  including growth  factor withdrawal  from he- 
matopoietic  cell  lines  (2),  corticosteroid  or  antibody- 
induced thymocyte ablation in vivo (3,  4),  and oncogene 
transfection of cell lines  (5,  6).  Although Bcl-2 has  been 
proposed to function by a variety of means, including pro- 
tection from oxidative damage due to cellular metabolism 
(7), or through the inhibition of activators of the cell death 
program such as bax or ICE (8), the mechanism of this re- 
sistance  remains unclear. 
It is becoming clear that many proteins that can induce 
PCD are in fact components of the cell division cycle, and 
that the cell cycle and PCD  are inextricably linked  (for a 
review see reference 9). Most conspicuously, expression of 
c-myc  has  been  shown  to  initiate  both  proliferation  and 
1Abbreviations used in this paper: BrdU, 5-bromo-2'-deoxyuridine;  CAS, 
concanavalin A supematant; DPBS, Dulbecco's  phosphate-buffered  saline 
solution; LN, lymph node; PCD, programmed cell death; PE, phyco- 
erythrin; PI, propidium iodide; pRb, protein retinoblastoma. 
PCD  in vitro  (10).  Interestingly, the same regions  of the 
Myc protein known to be required for the more conven- 
tional  consequences of Myc expression (i.e., mitogenesis) 
were required for the induction of PCD. Expression of the 
homeobox fusion gene E2A-PBX1  (resulting from a t(1;19) 
chromosomal  translocation  in  certain  human  leukemias) 
can also  reduce both proliferation and PCD  in vivo (11). 
Expression of the tumor suppressor protein retinoblastoma 
(pRb),  a  known  regulator  of cell  cycle progression,  has 
been shown to repress PCD induced by radiation (12). En- 
forced expression of the  transcription  factor E2F1  (a pri- 
mary target of pRb)  leads  to inappropriate  S phase  entry 
and  incomplete  DNA  synthesis,  which  is  terminated  by 
PCD  (13~j. Another tumor suppressor gene, p53, has been 
shown to be capable of the induction of  PCD (14), possibly 
through inducing the transcription of bax (15), a known posi- 
tive regulator of PCD  (16).  Senescent fibroblasts also  up- 
regulate many cell cycle related genes, such as c-fos,  c-myc, 
c-jun, and cdc2, prior to undergoing PCD (17); similar up- 
regulation of  proliferating cell nuclear antigen (PCNA), c-myc, 
p53, cyclin A, and cdc2 has been observed in cell lines in- 
duced to  undergo  PCD  (18).  In  another study,  two  pri- 
mary catalytic partners  of cyclin A  (cdc2 and cdk2)  have 
been shown to be activated in cell lines induced to undergo 
PCD  (19).  These and many other studies  thus  establish  a 
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sion cycle. 
In the experiments presented here, we demonstrate that 
bcl-2  gene  expression can  regulate  progression of the  cell 
cycle, in both primary tissues (in vivo and in vitro) and in 
continuous  cell lines.  In addition, we propose a  model to 
reconcile these findings with the known effects ofbcl-2, es- 
pecially the inhibition of PCD. Together, these data should 
help to  elucidate the means by which bd-2  inhibits PCD, 
and further provide insights into the relationship between 
PCD and cell division in both normal and malignant cells. 
Materials and Methods 
Mice.  Mice expressing a lymphoid-restricted  human bcl-2 trans- 
gene construct were generated as described (4),  and have since 
been extensively backcrossed onto the C57BL/6 background 006/ 
bcl-2). C57BL/6 and B6/bcl-2 transgenic mice used in the experi- 
ments described here were littermates from the mating of C57BL/6 
n-rice (Jackson Laboratories, Bar Harbor, ME) with B6/bd-2 het- 
erozygotes. 
Surface Immunophenotyping  and Cell Sorting.  These procedures were 
performed as previously described (20). 
Bromodeoxyuridine  Administration and Analysis.  5-bromo-2'-deox- 
yuridine 00rdU; Sigma, St. Louis, MO) was prepared fresh daily, 
and was administered at 0.8 mg/ml in the drinking water. No ad- 
verse affects of this treatment (e.g., weight loss or thymic atrophy) 
have been observed, in agreement with the published findings of 
others (21). Following the appropriate feeding interval, thymuses 
were harvested and stained with anti-CD4 conjugated to phyco- 
erythrin  (PE)  and anti-CD8  conjugated to biotin, followed by 
CyChrome streptavidin (PharMingen, San Diego, CA), to allow 
the identification of CD4-8- or CD4+8 + cells. Stained cells were 
washed and fLxed for 72  h  at 4~  using 1% paraformaldehyde/ 
0.01% Tween-20 in Dulbecco's phosphate-buffered saline solu- 
tion, pH 7.2  (DPBS).  Following washing in DPBS,  fixed cells 
were treated for 90 rain at 37~  with DNAse I  (50 U/ml) in a 
solution of 10 mM HC1/4.2  mM MGC12/150  mM NaCl. Cells 
were again washed in DPBS, stained with FITC-conjugated anti- 
BrdU antibody 00ecton-Dickinson, Mountainview, CA), and an- 
alyzed on a FACScan  |  (Becton-Dickinson). 
In vitro T Cell Activation.  Lymph node (LN) T cells were pre- 
pared from pooled axillary and brachial LN from C57BL/6  or 
B6/bcl-2  mice by two sequential rounds of B cell depletion using 
anti-immunoglobulin-coated Dynabeads (Dynal, Oslo, Norway). 
T  cells prepared in this fashion were >95% pure, as assessed by 
flow cytometry using anti-TCR antibody (not shown). 24-well 
tissue  culture trays were coated with purified anti-TCR-13 anti- 
body (clone H57-597;  Caltag Laboratories, South San Francisco, 
CA) by incubation for 1 h at 37~  in DPBS containing antibody 
at 25  I~g/ml, followed by washing with DPBS.  Purified T  cells 
were resuspended at 1.2  ￿  10  6 cells/ml in RPMI  1640  medium 
containing 10% FBS, 2 mM glutamine, 5 ￿  10 -5 M 13-mercapto- 
ethanol, and 10% rat concanavalin A supernatant (CAS). 1 ml of 
cells per well was dispensed into anti-TCR-coated trays, as above. 
Cells were harvested after the appropriate interval, assessed mi- 
croscopically  for cell number and viability, and fixed and analyzed 
as described below. 
DNA Content~Cell Cycle Distribution Analysis.  For DNA  con- 
tent analysis only, cells were washed in DPBS, resuspended in 50 p,1 
of DPBS,  slowly added to  1 ml  of ice-cold 70%  ethanol,  and 
stored overnight at 4~  After this fixation step, cells were centri- 
fuged and resuspended in 2 N  HC1/0.5% Triton X-100 in H20 
for 30 rain at room temperature. After denaturation, cells were 
again centrifuged and resuspended in 0.1 M Na2B407,  pH 8.5, to 
neutralize the acid. Cells were washed in DPBS/5%  FBS/0.5% 
Tween-20 and resuspended in propidium iodide (PI, 5 p,g/ml in 
DPBS) for at least 2 h before analysis on a FACScan  |  00ecton- 
Dickinson). For DNA content analysis  and simultaneous BrdU 
quantitation, cells were stained with FITC-conjugated anti-BrdU 
00ecton-Dickinson) prior to the addition of PI/DPBS, as above. 
Cell Lines and In Vitro BrdU Labeling.  FDC-P1 cells infected with 
a retroviral construct containing the human bcl-2 gene or a con- 
trol retroviral construct were generated as described (2). Both lines 
were grown in Dulbecco's Modified Eagles Medium (DMEM) con- 
taining 10% FBS, recombinant IL-3 (22), and selective antibiotics 
(G418,  500  mg/ml; Sigma); selective medium was removed for 
3-4 cell divisions before the initiation of experiments. Both con- 
trol and bcl-2-expressing cell lines were periodically and routinely 
subcloned by limit dilution. To minimize the effects  of culture 
differences and to maximize culture integrity, cells were passaged 
every 12 h for several days before use for experimentation. Pulse 
labeling with BrdU was accomplished by addition of BrdU to a 
final concentration of 10 IxM, followed by incubation for 40 rain 
under normal culture conditions, and subsequent resuspension of 
labeled cells in conditioned medium without BrdU. After the ap- 
propriate  intervals,  cells  were  fixed  and  stained  as  described 
above. 
Protein Immunoblot Analysis.  Cells were washed twice in DPBS 
containing 20 mM EDTA (DPBSE). Following the second wash, 
cell pellets were lysed for 5 rain at 96~  using a solution of 62.5 
mM Tris, pH 6.8/700 mM ~-mercaptoethanol/10% glycerol/2.3% 
SDS/0.001% bromophenol blue (4 ￿  107 cells/ml). Extracts were 
cooled on ice, and DNA was sheared by 3-4 passages through a 
28-gauge needle. Extracts were centrifuged at 45,000 g for 20 rain 
to remove insoluble material, and the supernatants were electro- 
phoresed on  7.5%  acrylamide minigels (7.3  ￿  8  cm)  using 25 
mM  Tris/192  mM  glycine/0.1%  SDS  buffer.  Gel  lanes  were 
loaded with equivalent volumes of cell extracts (generally 4 ￿  10 s 
cell equivalents/lane). Nuclear extracts from PMA-treated NIH/ 
3T3  cells (Santa Cruz), or extracts from FDC-P1  cells 3 h  after 
release from an M  phase block (Nocodazole, 40 p~g/ml; Sigma) 
were included as pRb controls where appropriate. After electro- 
phoresis,  the  proteins were  transferred  to  nitrocellulose mem- 
branes (HyBond ECL; Amersham, Arlington Heights, [L) using a 
Mini Trans-Blot apparatus (Bio-Rad, Hercules, CA) according to 
the manufacturers instructions. Membranes were immunoblotted 
with rabbit polyclonal antibody to ptkb (no. SC-50; Santa Cruz 
Biotechnology, Santa Cruz,  CA)  followed by HRP-conjugated 
goat anti-rabbit IgG (Santa Cruz) according to the manufacturers 
recommendations. Immunoblots were visualized using ECL de- 
tection (Amersham) according to the manufacturers recommen- 
dations. The film images were scanned using a laser scanning den- 
sitometer (Bio-Rad); quantitative analysis of the scanned images 
was performed using Molecular Analyst software (Bio-Rad). 
Statistics.  Statistical differences were  analyzed where  appro- 
priate using the Student's two-tailed t test for independent samples. 
Results 
The Kinetics  of In  Vivo  DNA  Labeling  in Normal and bcl-2 
Transgenic Littermate Mice.  The results of in vivo labeling 
of thymocyte DNA,  using  continuous  BrdU  feeding and 
anti-BrdU  antibodies,  are shown  in  Fig.  1.  Since  thymus 
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Figure 1.  The kinetics of in vivo labeling offlzymocyte DNA in bcl-2 
transgenic or control mice. Transgenic or control mice were fed BrdU in 
the drinking water for the periods indicated, followed by immunofluores- 
cent staining of thymocytes for surface CD4/8 and nuclear BrdU and flow 
cytometry. Both CD4-8- cells (most of  which are dividing) and CD4+8 + 
cells (most of which have stopped dividing) were slower to label in bcl-2 
transgenic mice (solid  circles)  than in control littermates (open squares). The 
differences in time until half-maximal labeling are indicated by hatched 
vertical lines, and represent an ~60% time lag in transgenic cells, regard- 
less  of developmental  stage. Differences were  statistically significant 
(P <0.05)  at all logarithmic phases of labeling. Data points represent the 
arithmetic mean + standard deviation for at least three experiments. 
size,  thymic  subset  ratios,  and  T  cell surface  markers  ex- 
pression  (including  CD3/TCR)  are  indistinguishable be- 
tween bcl-2 transgenic mice and their non-transgenic litter- 
mates (4), the direct assessment of isogenic bcl-2  expression 
can be made both in vivo and in vitro. The labehng pattern 
for  CD4-8-  cells  was  essentially log  phase,  and  that  of 
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Figure  2.  Cell  cycle distribution  of ex vivo  thymocytes from bcl-2 
transgenic or control mice. CD4-8- and CD4+8 + thymocytes were pre- 
pared from transgenic or control mice by cell sorting. The DNA content of 
sorted cells  was analyzed by propidium iodide staining and flow cytome- 
try. In both cases, cells from bcl-2 transgenic mice (solid bars) had more 
cells in G0/G I phase, and proportionally fewer cells in S phase, than their 
normal littermates (open bars); these differences  were statistically  significant 
(P <0.05). No differences in the proportions of M phase cells were ob- 
served (P >0.1).  Data points represent the arithmetic mean +  standard 
deviation for at least three experiments. 
CD4+8 +  essentially linear,  in  both  types  of mice,  as  ex- 
pected for dividing and non-dividing populations, respec- 
tively (23).  Further, both CD4-8-  and CD4+8 + cells ulti- 
mately labeled to the same maximal level in both types of 
mice. These findings again demonstrate the general devel- 
opmental equity between transgenic and control animals (4). 
Nonetheless, a  substantial lag in DNA  labeling, represent- 
ing an approximate 60% increase in the time required be- 
fore  half-maximal labeling,  was  found  in  bcl-2  transgenic 
thymocytes. The bd-2-induced  delay in DNA labehng was 
consistent in both the largely dividing CD4-8-  cells and in 
their mostly non-dividing CD4§  + progeny (Fig. 1). These 
results show that the singular expression of a bd-2 transgene 
can profoundly affect thymocyte turnover,  resulting in an 
~60%  increase in the time required for comparable levels 
of DNA synthesis (i.e., cell division) in transgenic mice. 
Relative  Cell  Cycle Distribution  of Thymocytes from  Normal 
or bcl-2 Transgenic Ia'ttermate Mice.  Healthy dividing cells pos- 
sess a  variable amount  of nuclear DNA,  ranging from  the 
normal  (2n)  amount  found  in  most  somatic  cells,  up  to 
twice that amount (4n) in cells preparing to undergo mito- 
sis.  Measurement  of the  DNA  content  profile in  a  given 
population of cells can thus provide an estimate of the rela- 
tive cell division status; again, the similarities in thymocyte 
cell number and subset ratio allow a direct comparison be- 
tween  bcl-2  transgenic  and  non-transgenic  mice  (4).  The 
results  of this  type of analysis, using purified CD4-8-  or 
CD4§  +  thymocytes,  are  shown  in  Fig.  2.  Thymocytes 
from bcl-2  transgenic mice showed significantly (P <0.05) 
more cells with 2n DNA  content (i.e., G0/G 1 stage of cy- 
cle),  and proportionally fewer  cells in  S  phase;  no  differ- 
ences  (P  >0.1)  were  observed  in  the  frequency  of cells 
with 4n DNA  content  (G2/M phases).  Statistically signifi- 
cant  differences in  the  G1  and  S  phase  distributions were 
observed in CD4+8 +  as well as CD4-8-  cells; differences 
in  the  former  finding  are  even  more  striking when  one 
considers that only a small proportion (~10%)  of these cells 
are dividing. These findings add further support to the con- 
cept that  bcl-2  gene  expression may affect the  thymocyte 
cell division cycle, and provide additional evidence to suggest 
that this effect is directed towards the GI/S phase transition. 
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sent the arithmetic mean +  standard deviation for three to four experi- 
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Control T  Cells Activated In Vitro.  Peripheral  T  lymphocytes 
from the  LN  of both bcl-2  transgenic and normal animals 
are mostly resting cells with 2n DNA content. Using anti- 
TCR.-coated plastic trays and cytokines, resting T  cells (Go) 
can be activated in vitro,  an event which  is followed by 
DNA synthesis and cell division. The rate of this transition 
can be monitored through kinetic analysis of cellular DNA 
content, as described in the preceding section. The results 
of such analyses are shown in Fig. 3. Activated cultures of 
LN T  cells from bd-2 transgenic mice were slower to move 
out of G0/G1 phases of cycle, and proportionally slower to 
move  into  S  phase.  The  differences between bd-2  trans- 
genic  and  control  cultures  were  statistically  significant 
(P <0.02)  at all times points where proliferation could be 
detected (i.e., 24 h  and onward). Experiments were termi- 
nated at  48  h,  before  the  occurrence of any cell division 
and  concomitant reversion to  the  2n  stage.  Since  the  in 
vitro response of T  cells from bcl-2  transgenic mice is even 
more  robust  than  that  of T  cells  from  normal mice  (4), 
these differences in the kinetics of cell cycle progression are 
even more profound. Thus, these experiments provide ad- 
ditional evidence that bcl-2 gene expression can inhibit pro- 
gression of the  cell division cycle.  Further,  these  in vitro 
experiments eliminate the possibility that feedback inhibi- 
tion due to prolonged CD4+8 + cell survival was responsi- 
ble for the  observed inhibition of thymocyte cell division 
in bcl-2  transgenic mice (Figs.  1 and 2),  since homeostatic 
controls are not in effect in culture. Additional evidence for 
this finding is provided in the next section. 
Effects of Ectopic bcl-2 Gene Expression  on Cell Cycle Progres- 
sion in Continuous  Cell Lines.  To support the results obtained 
using primary tissues from bcl-2 transgenic and control mice 
(Figs.  1-3), defined in vitro systems were sought. Isogenic 
FDC-Pl myelocytic cell lines expressing bd-2-containing or 
control retroviral constructs have been described previously 
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Figure 4.  Kinetics of progression of bcl-2-expressing or control cells through the stages of cell cycle. S phase cells from bd-2-expressing or control 
FDC-P1 cultures  were labeled using a 40-min pulse of BrdU. The transit of labeled cells through the cell cycle was followed by simultaneous  analysis  of 
BrdU incorporation  and DNA content using flow cytometry. Cells expressing bcl-2 (A, lower series) moved into G2, M, and G~ phases of cell cycle at the 
same rate as controls (upper series). However, the reentry of labeled cells into S phase (beginning  at 6 h in controls) is delayed in bd-2 expressing  cells. B 
graphically depicts this effect, by comparing the rate of exodus and subsequent  reentry of BrdU  + cells through S phase (defined  by the hatched area 
marked in A, time 0 control); both cell types moved out of S phase at the same rate, but reentry was delayed in bcl-2  + cells (solid circles). The approxi- 
mate times for complete cell cycle (~14 h), G2 + M + G1 phases ("~6 h), and the bcl-2-induced lag in S phase reentry (~2 h) are indicated.  Data points 
represent the pooled arithmetic mean  for two experiments. 
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sion can be compared in the absence of other contributing 
factors. Using a 40-rain pulse of BrdU, we followed the pro- 
gression of an essentially synchronous population of S phase 
cells  throughout  the  phases  of cell  cycle,  as  measured  by 
DNA  content  analysis  (Fig.  4).  Both  bcl-2-expressing  and 
control FDC-P1  cells labeled with BrdU to approximately 
the same extent during the pulse (A, time 0  h); this finding 
attests to the initial good health of the two starting popula- 
tions,  since they have just passed the  G1  to S phase  check- 
point.  The analysis of labeled cells through  a single cell cy- 
cle  ensures  that minimal DNA  damage  and  cell  death  can 
occur,  and  ehminates  the  possibihty  that  any  delay  in  cell 
cycle  progression  simply  represents  prolonged  survival  of 
damaged  or  dying  cells  by  bd-2.  The  progression  of both 
types  of cultures  out  of S  phase,  and  into  first  G2/M  (4n 
DNA  content),  and  then  G0/G1  (2n  DNA  content),  is  the 
same  (2-6  h).  However,  the  reappearance  of BrdU +  cells 
into S phase is slower in bcl-2-infected cells than in control 
cells, as can be seen beginning at 6 h. The results are graph- 
ically  represented  in  panel  B,  by  plotting  the  exodus  of 
BrdU-labeled  (i.e., S phase) cells out of and then back into 
S phase; exodus is identical in both cell types, while reentry 
is  delayed  in  bcl-2  infected  cells.  Since  the  transit  from  S 
phase through G2/M and into G1 is the same in both types of 
cells (A and B, 0-6 h), the differences in the kinetics of reen- 
try into  S  phase  must  occur  at  the  G1/S  phase  transition. 
The  G1  phase  of cell  cycle  in  FDC-P1  controls  is  ~5  h 
(Fig.  4  A,  and  additional  data not shown).  Thus,  the lag in- 
duced by bcl-2 (~2 h)  increases the length  of G1 by ,"~40%, 
a value consistent with the delay found using the in vivo la- 
beling  system  described  above  (Fig.  1).  Such  an  increase 
must  be  considered  to  be  very  substantial  in  biological 
terms;  by  comparison,  multiple  ectopic  expression  of the 
predominant  G 1  cyclins  D2  and  D3  only  changes  the 
length  of G 1 by  28%  in  a  similar  system  (23).  The  data 
shown  in  Fig.  4  thus  provide  a  clear demonstration  of the 
inhibition  of cell cycle progression by bcl-2, at precisely the 
stage of cell cycle which  is critical to the decision between 
continued  cell  division  or the  induction  of PCD  (i.e.,  the 
G~/S  transition).  Further,  these  experiments  demonstrate 
that  such  inhibition  is  not  bruited  to  thymocytes  or  even 
lymphocytes,  but  is  apparently  a  pervasive  effect  in  re- 
sponse to bcl-2 expression. 
Differential  Phosphorylation of Rb Associated with bcl-2 Gene 
Expression.  The  regulation  of mammalian  cell  cycle pro- 
gression  has  been  extensively  studied  in  recent  years.  In 
particular,  many insights have been gained in regard to the 
G1/S phase transition  (25). One of the key regulators of this 
transition is the retinoblastoma protein, pR.b. Phosphoryla- 
tion  of pRb  (pRb-P)  leads  to  the  liberation  of key  tran- 
scription  factors  required  for DNA  synthesis,  whereas  de- 
phosphorylation  is generally  representative  of cell  division 
cycle arrest before  or near the  G1/S restriction  point  (25). 
Thus,  the ratio of pR.b-P  to pRb  can be used as a  relative 
indication  of cell cycle status.  The results ofpRb  immuno- 
blot analysis, using various bcl-2 expressing and control cells, 
are shown in  Figs.  5  and  6.  Control  FDC-P1  cells express 
almost exclusively the phosphorylated form ofpRb  (Fig. 5, 
lane  3),  consistent  with  their  extremely rapid cell division 
time of"~12-14  h  (see Fig.  4);  the ratio of pRb-P/pRb  is 
~4.1.  FDC-P1/bcl-2  cells,  on  the  other  hand,  express ap- 
preciable  levels  of the  underphosphorylated  forms of plLb 
(Fig.  5,  lane  4).  The  pRb-P/pRb  ratio  in  these  cells  is 
~2.5,  nearly twofold less than that found in controls,  con- 
sistent  with  a  less  rapid  cell  cycle status.  Since  the  regula- 
tion  of cell  cycle  progression  through  the  G1  restriction 
point  by pP,.b  is represented  by a  threshold,  rather  than  a 
hnear titration  (25), a twofold increase is likely to represent 
a  functional  difference.  In  any  case,  even  more  profound 
differences in phosphorylation  ofplLb can be seen using ex 
vivo tissues from bcl-2 transgenic and control mice (Fig.  6), 
as discussed below. 
Immature CD4-8-  thymocytes can be subdivided into sev- 
eral  groups,  which  differ mainly with  respect  to  the  rear- 
rangement status of their TCR.-13 loci (26).  CD24+25+441~ 
CD4-8-  cells  are  slowly  cycling  and  endogenous  bcl-2+; 
their  immediate  progeny  (CD24+25-44 l~ CD4-8-  cells) 
are rapidly dividing and endogenous  bcl-2-  (23, 26).  Thus, 
the comparison of these two cell types from bcl-2 transgenic 
or control mice allows the clear assessment of the effects of 
bd-2  expression  on  cell cycle status  during  normal cell de- 
Figure 5.  Relative pRb phos- 
phorylation  in  continuous  cell 
hnes  expressing ectopic  bcl-2 
genes or control  vectors. Fig. 5 
shows a pRb immunoblot analy- 
sis  of bcl-2-expressing FDC-P1 
cells  and  retrovirus-ordy  con- 
trols.  Lanes  I  and  2  (PMA- 
treated  NIH/3T3  nuclear ex- 
tracts, and early  Gl-phase FDC-P1 
extracts,  respectively) show the 
normal  location  of  under- 
phosphorylated pRb. Asynchro- 
nous FDC-P1 controls expressed 
phosphorylated  pRb (pRb-P) almost  exclusively  (lane 3). Ectopic bcl-2  expression  in these cells resulted in substantially higher levels of underphosphorylated 
pRb (lane 4), consistent with a general decrease in cell cycle status. Histograms show scanning densitometry of the irrtmunoblots; sohd hnes represent 
FDC-P1 control cultures, while hatched lines represent bcl-2-infected FDC-P1 cells. The shaded areas represent the approximate areas used for peak quan- 
titation of phosphorylated and underphosphorylated  pRb. 
2223  Mazel et al. Figure 6.  Relative plkb phos- 
phorylation in purified subsets of 
thymocytes from bcl-2 transgenic 
or control mice. CD24+25+441~ 
CD4-8  cells  are slowly cycling 
and endogenous bd-2+; their im- 
mediate progeny (CD24+25-44  l~ 
CD4  8  cells)  are rapidly divid- 
ing and endogenous bcl-2-, lm- 
munoblot  detection of pRb us- 
ing extracts of such cells purified 
from bcl-2 transgenic or control 
mice are shown in  Fig. 6.  The 
more  slowly  dividing  CD25 § 
cells exhibit primarily the under- 
phosphorylated  form  of  plLb 
(lanes  1 and 2); however, a de- 
tectable peak of phosphorylated 
pRb is also seen in control, but 
not transgenic,  animals.  The ratio 
of phosphorylated to underphos- 
phorylated  pRb  is  seven-fold 
higher in controls (see Results). 
After transition to the more rap- 
idly cycling CD25- stage, a substantial  shift in favor ofpP,.b-P is seen (lanes 3 and 4). However, the ratio ofphosphorylated to underphosphorylated ptLb 
is still four to five times higher in CD25- cells from control mice than in cells from bcl-2 transgenic mice. Histograms show scanning densitometry of the 
immunoblots; solid lines represent cells from control mice, while hatched lines represent cells from bcl-2 transgenic mice. The shaded areas represent the 
approximate areas used for peak quantitation ofphosphorylated and underphosphorylated pRb. 
velopment. The results of a pR.b immunoblot analysis of such 
cells are shown in Fig. 6. CD24+25+441~ CD4-8-  cells (en- 
dogenous  bcl-2 §  express mainly the  underphosphorylated 
form of pRb  in either transgenic  or control mice  (lanes  1 
and 2),  consistent with their slowly dividing status. None- 
theless, a substantial peak representing phosphorylated plkb 
is evident in control mice (plkb-P/pRb  =  0.7), as opposed 
to bd-2 transgenic mice (pRb-P/pRb  =  0.1), where essen- 
tially no pRb-P can be detected. Upon transit to the more 
rapidly dividing CD24+25-441~ CD4-8-  phenotype (endo- 
genous  bcl-2-),  a  dramatic shift in favor of phosphorylated 
pRb  is seen  (lanes 3  and  4).  However,  the  ratio  of phos- 
phorylated  to  underphosphorylated  pRb  in  control  mice 
(plkb-P/pRb  =  13.4)  is four to five times higher than that 
found in the same cells from bd-2 transgenic mice (pRb-P/ 
plkb =  3.1). Again, this pattern ofphosphorylation ofplkb 
is consistent with a general decrease in the ability of cells to 
transit the  G 1 restriction point in the presence  of bcl-2  ex- 
pression.  This  type  of controlled analysis of defined  bcl-2 
transgene  expression  in  the  context  of endogenous  bcl-2 
expression or repression,  using well-characterized ex vivo 
tissues,  thus  provides very  convincing evidence  that  bcl-2 
expression can  regulate  cell cycle progression in  a  signifi- 
cant physiological fashion. 
Discussion 
A  balance between  cell division and cell death is an in- 
herent  event  in  the  maintenance  of homeostasis.  Conse- 
quently, it is intellectually appealing to find that a single gene 
(i.e.,  bd-2)  may prove to be a  central regulator in both of 
these processes. In recent years, a strong biochemical linkage 
between PCD  and the cell division cycle has been emerg- 
ing (see Introduction). Meanwhile, the molecular means by 
which  bd-2  expression  can  regulate  PCD  remains  unre- 
solved. Part  of the  mystery almost certainly results from  a 
general failure to perceive PCD as a complex sequence of  bio- 
chemical events, rather than  as a  fixed phenotype.  Conse- 
quently, all of the proposed mechanisms, including a regu- 
lation of cell division cycle progression, may be found to play 
a role under the appropriate circumstances. In fact, the reg- 
ulation of cell cycle progression by bcl-2  can be readily ra- 
tionalized with the other proposed mechanisms for inhibition 
of PCD by bd-2.  For instance, retardation of G1  to S phase 
progression by bcl-2  may provide the necessary time to re- 
pair DNA damage induced by oxidative metabolism, rather 
than preventing DNA  damage per se. The involvement of 
bd-2  antagonists,  such  as  bax,  may  also be  reconciled;  for 
instance, p53  expression is stabilized by DNA damage, and 
p53 has been shown to be a positive regulator of bax tran- 
scription (15).  It is important to  emphasize that bd-2  does 
not appear to affect the absolute magnitude of cell division 
in vivo, or to  absolutely nullify the  execution of cell divi- 
sion cycle. Rather, it appears that bd-2 can affect the rate of 
cell cycle progression in a manner which may be sufficient 
to prevent the cell from undergoing PCD.  In this light, it is 
informative to note that enforced expression of oncogenes 
associated with proliferation (such as c-myc) are sufficient to 
drive cells into  PCD  in  a  manner  which  can be inhibited 
by bd-2  (5, 6). 
A  number  of antagonists of bd-2,  such  as bax and bcl-xs 
have been described (reviewed in reference 8).  The  inter- 
actions of these with bd-2 and bd-2 homologues appears to 
occur  in  a  stoichiometric  fashion  (8).  Consequently,  our 
studies cannot elucidate whether forced bcl-2  expression in- 
hibits  cell  cycle  progression  directly,  or  rather  indirectly 
through  interaction  with  one  of  these  other  proteins. 
However,  it is informative to  note  that  repression  of en- 
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sion are coincident events, both during T  cell development 
(26)  and after peripheral T  cell activation  (27).  In contrast, 
high level bcl-2  expression is found both in resting T  and B 
lymphocytes and  in their long-lived,  slowly dividing  thy- 
mocyte  precursors  (26).  Therefore,  differential  regulation 
of bcb2 appears be a prerequisite  for cell cycle progression 
in  lymphocytes.  The  finding  that  forced  bcI-2  expression 
also inhibits  cell cycle progression in a myelocytic cell line 
(Figs. 4  and 5) further supports a direct role for bd-2 in the 
regulation of cell cycle progression. 
Two other published reports regarding bcl-2  and the cell 
cycle merit attention in this discussion.  In the first (28), other 
investigators have found no differences in the in vivo label- 
ing of CD4+8 +  thymocytes from bcl-2  transgenic  or con- 
trol mice.  It is difficult to reconcile  these findings  directly 
with  ours.  However,  it is possible that no  real  differences 
exist  between  this  study  and  ours,  since  the  former  was 
based upon a single transgenic animal during the period over 
which most DNA labeling occurs (3 d). In the second study 
(29), it has been suggested that bcl-2  expression can poten- 
tiate cell division in a multiply transfected hematopoietic cell 
line.  The  biological  relevance  of such  a  highly  contrived 
system is difficult to assess.  However,  it is possible that the 
upregulation  of bcl-2  seen  after  mitogenic  stimulation  in 
these  cells is a protective response to allow cell cycle pro- 
gression  without  inducing  PCD,  rather  than  a  mandatory 
event in the induction  of cell cycle progression;  this is par- 
ticularly  true  since  the  mitogenic  stimulus  in  this  case  is 
IL-2.  This  explanation  is also supported  by the  published 
findings of others,  showing that growth factor receptor in- 
teraction is necessary to prevent PCD after the induction  of 
proliferation (10). 
In conclusion,  our studies suggest that bcl-2  may regulate 
the progression  of the  cell division cycle in lymphoid  cells 
(and possibly other tissue types) at a critical point where the 
decision between continued  cell cycle progression or PCD 
is made.  The prolongation  of the  cell division  cycle at the 
G1  to S phase transition  may thus help to explain  the well 
documented inhibition  of PCD by bcl-2,  by allowing addi- 
tional time for the  cell to prepare for DNA  synthesis and/ 
or  repair  DNA  damage.  The  enhanced  response  of bcl-2 
transgenic  T  cell  cultures  to in vitro stimuli  (4)  lends  fur- 
ther support to such a  concept.  The biochemical determi- 
nation of the upstream regulator(s)  of the cell cycle that are 
affected by bcl-2 will allow further elucidation  of this effect, 
and  may reveal important  clues  regarding  the  connection 
between  regulation  of the  cell  division  cycle and  PCD  in 
both normal and malignant cells. 
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